

Joanne L Blum

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2876208/publications.pdf>

Version: 2024-02-01

23
papers

1,488
citations

687363

13
h-index

752698

20
g-index

23
all docs

23
docs citations

23
times ranked

1830
citing authors

#	ARTICLE	IF	CITATIONS
1	Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline <i>BRCA1/2</i> -Mutated Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1383-1390.	7.0	12
2	Abstract P1-18-25: Real-world quality of life (QoL) in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), advanced breast cancer (ABC) treated with palbociclib: A patient-reported outcome (PRO) analysis from POLARIS. <i>Cancer Research</i> , 2022, 82, P1-18-25-P1-18-25.	0.9	0
3	Abstract P1-18-29: Male patients with hormone receptor positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) receiving palbociclib in the real-world: patient characteristics, treatment patterns, and outcomes from the POLARIS study. <i>Cancer Research</i> , 2022, 82, P1-18-29-P1-18-29.	0.9	1
4	Abstract P1-18-05: Early changes in circulating tumor DNA and its effect on clinical outcomes in patients with advanced breast cancer receiving the CDK4/6 inhibitor palbociclib: Genotyping results from POLARIS. <i>Cancer Research</i> , 2022, 82, P1-18-05-P1-18-05.	0.9	1
5	Abstract LB033: Longitudinal ctDNA changes in patients with long-term response to palbociclib combination therapy for advanced breast cancer: A preliminary analysis from the real-world POLARIS study. , 2021, , .		0
6	Talazoparib in Patients with a Germline <i>BRCA</i> -Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial. <i>Oncologist</i> , 2020, 25, e439-e450.	3.7	61
7	Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care Chemotherapy. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkz085.	2.9	24
8	Barriers to the utilization of genetic testing and genetic counseling in patients with suspected hereditary breast and ovarian cancers. <i>Baylor University Medical Center Proceedings</i> , 2019, 32, 340-344.	0.5	25
9	Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy in Early-Stage Invasive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 428-429.	1.6	1
10	The Clinical Utility of Next Generation Sequencing Results in a Community-Based Hereditary Cancer Risk Program. <i>Journal of Genetic Counseling</i> , 2017, 26, 105-112.	1.6	14
11	The incidence of cardiomyopathy in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers after anthracycline-based adjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2017, 162, 59-67.	2.5	16
12	Higher antitumor activity of trabectedin in germline <i>BRCA2</i> carriers with advanced breast cancer as compared to <i>BRCA1</i> carriers: A subset analysis of a dedicated phase II trial. <i>Breast</i> , 2017, 34, 18-23.	2.2	20
13	A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 163, 535-544.	2.5	16
14	A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 601-609.	2.5	25
15	Anthracyclines in Early Breast Cancer: The ABC Trials—USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). <i>Journal of Clinical Oncology</i> , 2017, 35, 2647-2655.	1.6	223
16	Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With <i>BRCA</i> Mutations. <i>JAMA Oncology</i> , 2016, 2, 1434.	7.1	189
17	A phase II trial of trabectedin in triple-negative and HER2-overexpressing metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 295-302.	2.5	16
18	Genomic alterations in DNA repair and chromatin remodeling genes in estrogen receptor-positive metastatic breast cancer patients with exceptional responses to capecitabine. <i>Cancer Medicine</i> , 2015, 4, 1289-1293.	2.8	7

#	ARTICLE	IF	CITATIONS
19	Pooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 136, 777-788.	2.5	42
20	Association of age and overall survival in capecitabine-treated patients with metastatic breast cancer in clinical trials. <i>Breast Cancer Research and Treatment</i> , 2011, 125, 431-439.	2.5	16
21	Two identical triplet sisters carrying a germlineBRCA1 gene mutation acquire very similar breast cancer somatic mutations at multiple other sites throughout the genome. <i>Genes Chromosomes and Cancer</i> , 2000, 28, 359-369.	2.8	22
22	Psychological and Behavioral Implications of Screening for Breast or Ovarian Cancer Predisposition Genes <i>BRCA1</i> and <i>BRCA2</i> . <i>Baylor University Medical Center Proceedings</i> , 1999, 12, 87-92.	0.5	0
23	Multicenter Phase II Study of Capecitabine in Paclitaxel-Refractory Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 1999, 17, 485-485.	1.6	757